Get the Stockscreener App
1.315
0.38%
-0.005
After Hours:
1.32
0.005
+0.38%
Geron Corp stock is traded at $1.315, with a volume of 4.62M.
It is down -0.38% in the last 24 hours and up +0.38% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$1.32
Open:
$1.32
24h Volume:
4.62M
Relative Volume:
0.63
Market Cap:
$839.44M
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-4.1094
EPS:
-0.32
Net Cash Flow:
$-216.50M
1W Performance:
-1.87%
1M Performance:
+0.38%
6M Performance:
-8.04%
1Y Performance:
-61.66%
1-Day Range:
$1.30
$1.34
1-Week Range:
$1.30
$1.36
52-Week Range:
$1.04
$3.495
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.315 | 842.63M | 29.48M | -201.19M | -216.50M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
Geron extends loan agreement deadlines for $250 million credit facility - Investing.com
Geron extends loan agreement deadlines for $250 million credit facility By Investing.com - Investing.com UK
Geron Signs Loan Agreement Amendment With BioPharma Credit - TradingView — Track All Markets
Geron Corporation (NASDAQ:GERN) Given Average Rating of "Hold" by Brokerages - MarketBeat
Geron (NASDAQ:GERN) Shares Cross Above 200 Day Moving AverageTime to Sell? - MarketBeat
Geron (NASDAQ:GERN) Trading Up 4.9%Time to Buy? - MarketBeat
Geron Corporation (GERN) restructuring to lower operating expenses as it eyes profitability in 2026 - MSN
How Geron Corporation stock compares to market leadersJuly 2025 Price Swings & Precise Buy Zone Identification - Улправда
Can Geron Corporation (GON) stock expand revenue streamsWeekly Trade Report & Smart Investment Allocation Insights - Улправда
What margin trends mean for Geron Corporation stock2025 Volatility Report & Weekly High Potential Alerts - Улправда
Geron: From Launch Hype To Later-Line Gravity (NASDAQ:GERN) - Seeking Alpha
Geron (NASDAQ:GERN) Shares Down 3.9%What's Next? - MarketBeat
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Geron Corporation (GERN) Restructuring to Lower Operating Expenses as it Eyes Profitability in 2026 - Yahoo Finance
Geron (NASDAQ:GERN) Stock Price Up 5.6%Here's What Happened - MarketBeat
14 Best Multibagger Penny Stocks to Buy Right Now - Insider Monkey
Geron Corporation (NASDAQ: GERN) plans workforce cuts, expects $18M charges - Stock Titan
Squarepoint Ops LLC Increases Stock Position in Geron Corporation $GERN - MarketBeat
Bay Area biotech company, down $1.7 billion in value, lays off a third of staff - SFGATE
Geron (NASDAQ:GERN) Trading Up 8.2%What's Next? - MarketBeat
Geron Stock (NASDAQ: GERN) News Today: Restructuring, Analyst Ratings, and 2026 Catalysts (Dec. 12, 2025) - ts2.tech
Geron stock falls as H.C. Wainwright reiterates Neutral rating amid restructuring - Investing.com
Praxis tees up another approval filing; Geron turns to layoffs - Yahoo Finance
Geron Corporation (NASDAQ:GERN) Nasdaq Composite ETF Clinical Trials - Kalkine Media
Geron Corporation (NASDAQ:GERN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Geron Corporation (GERN) Presents New Data at the 67th American Society of Hematology 2025 Annual Meeting - Finviz
Foster City drug maker Geron to lay off one-third of staff under new CEOSan Francisco Business Times - The Business Journals
Geron Corporation: Can Restructuring Bring The Stock Back To Life? I'm On Sidelines (GERN) - Seeking Alpha
Geron Corporation (GERN) Announces Significant Workforce Reducti - GuruFocus
Geron (GERN) Initiates Strategic Restructuring for Long-Term Gro - GuruFocus
Geron to cut workforce by one-third in strategic restructuring - Investing.com
Geron Corporation Announces Strategic Restructuring to Enhance RYTELO® U.S. Commercial Strategy and Reduce Operating Expenses - Quiver Quantitative
Geron (Nasdaq: GERN) plans one-third cut as 2026 operating expenses expected below 2025 - Stock Titan
Here’s Why Geron Corp. (NASDAQ:GERN) Crashed Today - MSN
Geron stock rating reiterated as Neutral by H.C. Wainwright - Investing.com
Geron (GERN) Highlights Promising ASH 2025 Data on RYTELO - GuruFocus
Geron reports early cytopenia may signal response in MDS patients - Investing.com
Geron Corporation Presents New Data on Imetelstat at ASH 2025, Highlighting Clinical Benefits in Lower-Risk Myelodysplastic Syndromes and Myelofibrosis - Quiver Quantitative
Geron (Nasdaq: GERN) presents ASH 2025 RYTELO data on LR-MDS cytopenias, survival trends - Stock Titan
How Geron Corporation (GON) stock correlates with oil marketsWeekly Gains Report & Daily Profit Focused Screening - Newser
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - Benzinga
What consensus target says about Geron Corporation (GON) stockJuly 2025 EndofMonth & High Conviction Buy Zone Picks - Newser
Will Geron Corporation (GON) stock keep raising dividends2025 Investor Takeaways & Reliable Volume Spike Alerts - Newser
Why Geron Corporation (GON) stock stays on buy listsStop Loss & Daily Stock Trend Reports - Newser
Geron Corporation $GERN Stake Increased by Geode Capital Management LLC - MarketBeat
Great week for Geron Corporation (NASDAQ:GERN) institutional investors after losing 71% over the previous year - simplywall.st
Geron Corporation (NASDAQ:GERN) is favoured by institutional owners who hold 64% of the company - Yahoo Finance
Geron Corporation $GERN Shares Sold by Segall Bryant & Hamill LLC - MarketBeat
Wall Street Turns Bullish on Geron Corporation (GERN) amid Rytelo Sales Push Plans - Insider Monkey
10 Fastest Growing Penny Stocks to Buy Now - Insider Monkey
Geron Corporation (GERN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Geron Corp Stock (GERN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LAWLIS V BRYAN | Director |
May 09 '25 |
Buy |
1.18 |
13,300 |
15,667 |
13,300 |
| Samuels Scott Alan | EVP, Chief Legal Officer |
Feb 27 '25 |
Buy |
1.61 |
15,000 |
24,150 |
26,682 |
| SCARLETT JOHN A | Chairman, President and CEO |
Feb 27 '25 |
Buy |
1.76 |
12,500 |
22,062 |
12,500 |
| Ziegler James | EVP, Chief Commercial Officer |
Feb 27 '25 |
Buy |
1.60 |
100,000 |
160,000 |
100,000 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):